SCYNEXIS (SCYX) to Release Quarterly Earnings on Thursday

SCYNEXIS (NASDAQ:SCYX) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $10.19 million for the quarter.

SCYNEXIS (NASDAQ:SCYX) last released its earnings results on Wednesday, March 12th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.13. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%. The company had revenue of $0.98 million for the quarter.

SCYNEXIS Stock Down 1.0 %

Shares of NASDAQ:SCYX opened at $1.03 on Wednesday. SCYNEXIS has a 52-week low of $0.82 and a 52-week high of $3.07. The stock has a market cap of $40.15 million, a price-to-earnings ratio of -1.39 and a beta of 1.67. The business has a 50-day moving average price of $1.06 and a 200-day moving average price of $1.23.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of SCYNEXIS from a “hold” rating to a “sell” rating in a research note on Saturday.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.